Health officials are closely monitoring the highly mutated COVID-19 variant BA.3.2, nicknamed "Cicada," after detections in wastewater samples from at least 25 U.S. states and clinical cases as of early 2026. The Omicron descendant, first identified in South Africa in November 2024, has raised concerns over potential immune escape but has not yet driven a surge in severe illness or hospitalizations nationwide.

Cicada COVID Variant BA.3.2 Spreads in 25 US States: Key
Cicada COVID Variant BA.3.2 Spreads in 25 US States: Key Facts, Symptoms, Risks

The Centers for Disease Control and Prevention detailed the variant's spread in a March 19, 2026, report in its Morbidity and Mortality Weekly Report. BA.3.2 carries roughly 70 to 75 substitutions and deletions in the spike protein compared with JN.1 lineages used in the 2025-2026 vaccines, prompting laboratory studies suggesting reduced neutralization from existing antibodies.

As of February 11, 2026, the variant appeared in 23 countries, with notable rises in parts of Europe. In the U.S., it was first detected June 27, 2025, in a traveler arriving at San Francisco International Airport from the Netherlands. The initial clinical sample from a U.S. patient came January 5, 2026. Wastewater surveillance later identified it across diverse states, indicating broader circulation than confirmed cases suggest.

Origin and Nickname

Researchers coined "Cicada" because the variant remained largely undetected for months after its initial identification, much like the insect that spends years underground before emerging. It descends from the earlier BA.3 Omicron subvariant that circulated briefly in 2021-2022 before fading. BA.3.2 represents a genetically distinct lineage, separate from dominant JN.1 offshoots like XFG.

Two sublineages, BA.3.2.1 and BA.3.2.2, have been noted, with ongoing evolution observed. The World Health Organization placed it on its variants under monitoring list in December 2025, citing the high mutation count and potential antibody evasion without evidence of a clear growth advantage or increased severity at that time.

Spread in the United States

Wastewater samples detected BA.3.2 in 132 sites across 25 states by February 11, 2026, including California, New York, New Jersey, Michigan, Florida, Texas, Hawaii and others. Additional findings included four traveler nasal swabs, three airplane wastewater samples and five clinical respiratory specimens from four states.

By mid-March, some trackers showed detections in up to 29 states and Puerto Rico, though overall prevalence remained low — around 0.19% to 0.55% of sequenced samples in national surveillance from December 2025 to March 2026. In contrast, certain European countries saw BA.3.2 reach 10% to 40% of sequences between November 2025 and January 2026.

National COVID-19 case levels stayed relatively low in early 2026, with other Omicron subvariants still dominant. Experts emphasize that wastewater signals often precede clinical detections, serving as an early warning system.

Symptoms of the Cicada Variant

Symptoms linked to BA.3.2 mirror those of other recent Omicron subvariants and generally remain mild, especially in vaccinated or previously exposed individuals. Common reports include:

  • Cough
  • Fatigue
  • Runny nose or congestion
  • Headache
  • Sore throat
  • Mild fever or chills
  • Body or muscle aches

No data indicates BA.3.2 causes more severe disease than circulating strains. Hospitalized cases identified so far involved older adults with underlying conditions or a young child receiving outpatient care; all survived. Doctors note that sore throat sometimes appears prominent.

Risk Factors and Immune Escape Concerns

The primary concern stems from the variant's mutations potentially reducing protection from prior infection or the 2025-2026 vaccines targeting LP.8.1 antigens. Laboratory studies showed lower antibody neutralization against BA.3.2 compared with JN.1 strains, though real-world effectiveness data is still emerging.

Higher-risk groups include:

  • Older adults, particularly those 65 and older
  • People with comorbidities such as heart disease, diabetes or weakened immune systems
  • Unvaccinated or under-vaccinated individuals
  • Those with recent waning immunity

Prevention and Public Health Response

Health officials recommend staying up to date with COVID-19 vaccination, including the 2025-2026 formulation. While it offers the best protection against severe outcomes from current strains, its effectiveness against BA.3.2 may be somewhat lower. Additional layers of defense include:

  • Testing when symptomatic
  • Improved indoor ventilation
  • Masking in crowded or high-risk settings
  • Hand hygiene and respiratory etiquette

Broader Context in 2026

Six years after the pandemic's start, COVID-19 remains endemic, causing millions of illnesses and thousands of deaths annually in the U.S. Seasonal patterns and new variants continue to influence transmission. BA.3.2's slow emergence highlights how SARS-CoV-2 can evolve in under-monitored lineages before gaining traction.

Public health messaging focuses on preparedness rather than alarm. Most infections produce mild illness, and existing tools — vaccines, antivirals and basic precautions — help mitigate risks. WastewaterSCAN and similar projects have proven valuable for early detection.

For individuals, monitoring personal symptoms and consulting healthcare providers for testing or treatment remain key. Those at higher risk should discuss booster timing with their doctor.

As spring progresses, officials will watch whether BA.3.2 gains ground or remains a minor player. Continued vigilance, vaccination and surveillance will guide responses to this and future variants.

While Cicada adds another chapter to COVID-19's evolution, current evidence suggests it does not signal an immediate major threat. Americans can reduce personal risk through familiar preventive steps while public health systems track its trajectory.